Genomic ascertainment of PALB2 -related cancer predisposition
BACKGROUND: Cancer risk arising from a germline pathogenic PALB2 variant ascertained through a personal or family history of cancer has been well-studied. Here, we used genomic ascertainment to quantify PALB2-associated cancer risk, age-specific penetrance, all-cause and cancer-specific mortality. METHODS: We conducted a case-control study in two large population-based adult cohorts: the UK Biobank (n = 469,580) and Geisinger MyCode (n = 167,050). PALB2 P/LP heterozygotes were identified via exome sequencing and compared with non-carriers. Cancer diagnoses and vital status were obtained from linked registry and electronic health record data. We used multivariable logistic regression to estimate odds ratios for cancer outcomes and Cox proportional hazards models to estimate hazard ratios for all-cause mortality. Age-specific cumulative incidence (penetrance) was estimated using Kaplan-Meier methods. Models were adjusted for birth year, sex (when applicable), smoking status, and body mass index. RESULTS: PALB2 P/LP variant prevalence was 1:571 in UK Biobank and 1:940 in MyCode, with the higher prevalence in the UK cohort driven by the PALB2 p.Trp1038Ter founder variant. Compared with non-carriers, heterozygotes had significantly increased odds of any cancer, female breast cancer and pancreatic cancer, in both cohorts (P < 0.01). Adjusted hazard ratios for any cancer and female breast cancer ranged from 1.7 to 3.6. All-cause mortality was increased among PALB2-heterozygotes (HR 1.61-1.67), and survival after cancer diagnosis was reduced. Family history further modified cancer risk. CONCLUSIONS: Genomic ascertainment of PALB2-heterozygotes identifies elevated risk for multiple cancers and increased all-cause and cancer-specific mortality, although risks were lower than estimates from familial ascertainment.
Authors
- Hyokyoung Grace Hong (ORCID: https://orcid.org/0000-0002-4280-6243)
- J. Li
- Lisa J. McReynolds (ORCID: https://orcid.org/0000-0002-1018-1453)
- Jeremy S. Haley (ORCID: https://orcid.org/0000-0002-3279-7873)
- Michael R. Sargen (ORCID: https://orcid.org/0000-0003-1039-2522)
- Marc D. Tischkowitz (ORCID: https://orcid.org/0000-0002-7880-0628)
- Douglas R. Stewart (ORCID: https://orcid.org/0000-0001-8193-1488)
- David J. Carey (ORCID: https://orcid.org/0000-0001-6404-1950)
- Jiang Li (ORCID: https://orcid.org/0000-0002-7006-1285)
- Jung Gil KIM (ORCID: https://orcid.org/0000-0001-6274-2841)
- Douglas Stewart
- David J. Carey
- Marc Tischkowitz
- Jung Kim
Institutions
- National Institute for Health and Care Research (GB)
- National Cancer Institute (US)
- Cancer Genetics (United States) (US)
- Geisinger Health System (US)
Publication Details
- Journal
- JNCI Journal of the National Cancer Institute
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1093/jnci/djag429
- Primary Topic
- BRCA gene mutations in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institute for Health and Care Research
- National Institutes of Health
- NIHR Cambridge Biomedical Research Centre
- National Cancer Institute